Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ISM Clear all
Completed Phase 3 Interventional

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

NCT00814073
View directory record Official record
Conditions
Indolent Systemic Mastocytosis
Interventions
Masitinib, Placebo, Best Supportive Care
Drug · Other
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Sacramento, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Jul 22, 2026, 2:38 PM EDT
Recruiting No phase listed Observational

An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)

NCT07264959
View directory record Official record
Conditions
Indolent Systemic Mastocytosis
Interventions
Not listed
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 22, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia

NCT02086786
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone ISM
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Jul 22, 2026, 2:38 PM EDT
Completed No phase listed Observational

Mast Cell Connect: A Registry for Patients With Mastocytosis

NCT02620254
View directory record Official record
Conditions
Mastocytosis
Interventions
Not listed
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
Not listed
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Jul 22, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

NCT03770273
View directory record Official record
Conditions
Indolent Systemic Mastocytosis
Interventions
sarilumab, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Jul 22, 2026, 2:38 PM EDT
Completed Phase 1 Interventional

Comparative Bioavailability of Risperidone

NCT03527186
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone ISM® 100 mg
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Long Beach, California • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Jul 22, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia

NCT03160521
View directory record Official record
Conditions
Acute Schizophrenia
Interventions
Risperidone ISM 75 mg, Risperidone ISM 100 mg, Placebo of Risperidone ISM
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
20
States / cities
Rogers, Arkansas • Cerritos, California • Garden Grove, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Jul 22, 2026, 2:38 PM EDT
Completed Phase 1 Interventional

Comparative Bioavailability of Risperidone.

NCT05179525
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone ISM® 100 mg, Risperdal 4mg Tablet
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Garden Grove, California • Gaithersburg, Maryland • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Jul 22, 2026, 2:38 PM EDT
Recruiting Phase 2Phase 3 Interventional

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT04910685
View directory record Official record
Conditions
Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis
Interventions
Elenestinib, Placebo
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 22, 2026, 2:38 PM EDT
Active, not recruiting Phase 2 Interventional

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

NCT05186753
View directory record Official record
Conditions
SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis, ISM, BMM, Smoldering Systemic Mastocytosis, Bone Marrow Mastocytosis
Interventions
Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B), Placebo Tablets
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 2:38 PM EDT
Active, not recruiting Phase 2 Interventional

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT03731260
View directory record Official record
Conditions
Indolent Systemic Mastocytosis
Interventions
Avapritinib, Placebo
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Jul 22, 2026, 2:38 PM EDT
Terminated Phase 4 Interventional Results available

Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders

NCT01033565
View directory record Official record
Conditions
Sleep Disorder
Interventions
Natrol
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
4 Years to 8 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Jul 22, 2026, 2:38 PM EDT
Not listed Phase 2 Interventional

Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

NCT04655118
View directory record Official record
Conditions
Myelofibrosis, Indolent Systemic Mastocytosis
Interventions
TL-895, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Aurora, Colorado • Rochester, Minnesota • Canton, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Jul 22, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension

NCT03870880
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone ISM 75 mg, Risperidone ISM 100 mg
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Rogers, Arkansas • Garden Grove, California • Long Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Jul 22, 2026, 2:38 PM EDT
Completed No phase listed Observational

Patient-Reported Outcome Questionnaire for Systemic Mastocytosis

NCT02380222
View directory record Official record
Conditions
Aggressive Systemic Mastocytosis (ASM), SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD), Mast Cell Leukemia (MCL), Smoldering Systemic Mastocytosis (SSM), Indolent Systemic Mastocytosis (ISM) ISM Subgroup Fully Recruited
Interventions
Interview
Other
Lead sponsor
Adelphi Values LLC
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Jul 22, 2026, 2:38 PM EDT